I This is with reference to the press release dated 9th December 2015 on the DCGI approval for Ledipasvir-Sofosbuvir. Hetero would like to clarify that there was an error in the brand name of the fixed-dose combination drug 'Ledipasvir-Sofosbuvir'. It was published as Ledisof.
We would like to inform you that the correct brand name of the product is 'Ledifos'.
We are sorry for the inconvenience caused